Rivaroxaban in Acute Coronary Syndromes: We Have a Compass and an Atlas, but Where Are We Headed?

Journal of the American Heart Association - United Kingdom
doi 10.1161/jaha.119.012014
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Recent Advances in Pruritus – What We Have Learned and Where Are We Headed

F1000 Medicine Reports`
2010English

Where Have We Been and Where Are We Going?

1998English

Drug Development for Alzheimer's Disease: Where Are We Now and Where Are We Headed?

The American Journal of Geriatric Pharmacotherapy
2009English

Harness the Synergy Between Targeted Therapy and Immunotherapy: What Have We Learned and Where Are We Headed?

Oncotarget
Oncology
2017English

Techniques for RNA Detection: Where Are We Headed?

Science
MultidisciplinaryPhilosophy of ScienceHistory
2014English

Community Education: Where We Have Been and Where We Are Going

Educational Considerations
1974English

Meiosis 2007 – Where Have We Got to and Where Are We Going?

Chromosome Research
Genetics
2007English

We Must Use the Knowledge That We Have to Treat Patients With Acute Coronary Syndromes

Circulation
Cardiovascular MedicinePhysiologyCardiology
2004English

Sequencing Technologies and Analyses: Where Have We Been and Where Are We Going?

iScience
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy